Merck, Daiichi Sankyo withdraw US application for lung cancer therapy

By Reuters News

Sept 25 (Reuters) - Merck MRK.N and Daiichi Sankyo 4568.T have voluntarily withdrawn their US application seeking accelerated approval for their experimental lung cancer therapy, the companies said on Friday.

The decision followed discussions with the US Food and Drug Administration, which determined that the data from a mid-stage clinical study did not satisfy requirements needed to support an early green light.

The therapy, called ifinatamab deruxtecan, was under review to treat adults with an aggressive condition known as extensive-stage small cell lung cancer whose disease had worsened after standard chemotherapy.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.